Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note issued on Friday. The brokerage set a “sell” rating on the stock.

Oragenics Price Performance

Shares of OGEN opened at $0.23 on Friday. The business has a 50-day moving average of $0.28 and a 200-day moving average of $0.33. The company has a market capitalization of $5.03 million, a price-to-earnings ratio of -0.03 and a beta of 0.85. Oragenics has a 1 year low of $0.22 and a 1 year high of $3.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.